[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639046":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":26,"centralContacts":26,"locations":38,"responsibleParty":57,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Tampere University Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dry cough","ACTIVE_COMPARATOR","Fluticasone propionate inhalation",[13,14],"Drug: Fluticasone propionate inhalation","Drug: Placebo inhalation",{"label":16,"type":10,"description":17,"interventionNames":18},"Productive (Wet) Cough","Amoxicillin-clavulanic acid oral suspension",[19,20],"Drug: Amoxicillin-clavulanic acid oral suspension","Drug: Placebo oral suspension",[22,27,30,34],{"type":23,"name":11,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Fluticasone propionate 125 micrograms (Trade name: Flixotide Evohaler)\n\nAdministration (all ages):\n\n125 micrograms (1 puff) twice daily via spacer\n\nDuration of treatment:\n\n2 months",[9],null,{"type":23,"name":17,"description":28,"armGroupLabels":29,"otherNames":26},"Amoxicillin-clavulanic acid oral suspension 80\u002F11.4 mg\u002Fml Cream-white, sweet-tasting suspension\n\nAdministration:\n\nOral, weight-adjusted dosing 50 mg\u002Fkg\u002Fday divided into two equal doses\n\nDuration of treatment:\n\n2 weeks",[16],{"type":23,"name":31,"description":32,"armGroupLabels":33,"otherNames":26},"Placebo inhalation","Evohaler training inhaler\n\n1. puff twice daily via spacer\n\n   Duration of treatment:\n2. months",[9],{"type":23,"name":35,"description":36,"armGroupLabels":37,"otherNames":26},"Placebo oral suspension","Syrspend oral suspension base thickened with microcrystalline cellulose, without active pharmaceutical ingredient, administered with the same weight-adjusted regimen.\n\nDuration of treatment:\n\n2 weeks",[16],[39],{"facility":40,"status":41,"city":42,"state":26,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Study Site: Tampere University Hospital (TAYS), Children's and Adolescents' Hospital Outpatient Paediatrics Unit P.O. Box 2000, FI-33521 Tampere, Finland","RECRUITING","Tampere","Finland","FI",{"type":46,"coordinates":47},"Point",[48,49],23.78712,61.49911,{"lat":49,"lon":48},[52],{"name":53,"role":54,"phone":55,"phoneExt":26,"email":56},"Eero Lauhkonen, MD, PhD","CONTACT","+358-44-4728600","eero.lauhkonen@pirha.fi",{"type":58,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100639046","phase-3-finnish-childrens-protracted-cough-100639046",false,"NCT07582549","Finnish Children´s Protracted Cough","A Randomized, Double-blinded Clinical Trial Comparing the Efficacy of Antibiotic or Inhaled Corticosteroid to Placebo in Children´s Protracted Cough","FINNCHICO","Inclusion Criteria:\n\n* Prolonged cough lasting continuously for more than 4 weeks\n* No chronic disease requiring continuous medication (i.e. a generally healthy child)\n* No previous physician-diagnosed condition associated with prolonged cough episodes\n* No physician-identified symptoms or findings suggestive of an underlying disease\n* No prior physician-diagnosed allergic reaction or other severe or life-threatening adverse reaction to the investigational medicinal products (fluticasone or amoxicillin-clavulanic acid)\n* No simultaneous participation in another clinical drug trial\n* Parents\u002Fguardians have sufficient spoken and written Finnish language proficiency\n* Written, voluntary informed consent provided by a parent or legal guardian\n\nExclusion Criteria:\n\nChildren with symptoms or findings suggestive of an underlying cause of cough, including:\n\n* A previously physician-diagnosed disease associated with prolonged cough\n* Clinical examination or history at the study visit raising suspicion of a disease associated with prolonged cough (positive \"cough pointers\")\n* Abnormal lung function test\n* Abnormal chest X-ray (peribronchial markings are permitted)\n\nAdditional exclusion criteria:\n\n* Prior physician-diagnosed allergic reaction or other severe or life-threatening adverse reaction to the investigational medicinal products\n* Simultaneous participation in another clinical drug trial\n* Prolonged cough that has resolved spontaneously prior to the study visit","ALL","1 Year","6 Years",{"count":71,"type":72},100,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","Prolonged cough lasting more than four weeks is common in children, but the best treatment is often unclear when no underlying disease can be found. This study aims to find out whether commonly used treatments help children with prolonged cough more effectively than placebo.\n\nChildren who take part will first undergo standard medical examinations, including lung function tests and a chest X-ray, to look for the cause of the cough. If no specific cause is found, the child may enter the study.\n\nChildren with a dry cough will be randomly assigned to receive either an inhaled corticosteroid (fluticasone) or a placebo inhaler for two months. Children with a wet or productive cough will be randomly assigned to receive either an oral antibiotic (amoxicillin-clavulanic acid) or a placebo medicine for 14 days. Neither the families nor the researchers will know which treatment the child receives during the study.\n\nThe main goal is to determine whether these treatments significantly reduce or stop the cough compared with placebo. The results will help improve treatment recommendations for children with prolonged cough and avoid unnecessary medication use.\n\nParticipation is voluntary, and parents provide written informed consent for their child.",[78],"Chronic Cough",[78,80,81,82,83,84,85],"Child","Fluticasone Propionate","Amoxicillin-Potassium Clavulanate Combination","Randomized Controlled Trial","Double-Blind Method","Phase III","2026-05-05",{"date":88,"type":89},"2026-05-13","ACTUAL",{"date":91,"type":89},"2025-12-22",{"date":93,"type":72},"2027-12",{"name":5,"class":6},1]